Cspc Megalith Biopharmaceutical Co.,ltd.

This study tests a new mRNA vaccine called SYS6017 to prevent shingles, a painful rash caused by the chickenpox virus. About 800 healthy adults aged 40 and older will receive either the new vaccine, a placebo, or an existing shingles vaccine. Researchers will check how well the v…

This Phase 3 trial tests whether adding the experimental drug SYS6010 to standard immunotherapy can better prevent lung cancer from returning after surgery. About 570 adults with stage II-IIIB non-small cell lung cancer who did not respond well to pre-surgery treatment will be ra…

This study tests a new drug combination (SYS6010 plus enlonstobart) against the usual immunotherapy with chemotherapy for people with a type of advanced lung cancer that has a specific marker (PD-L1 positive). About 500 adults aged 18-75 who have not had prior treatment for their…

This study tests a new drug (SYS6006) combined with another drug (Enlonstobart) in people with advanced solid tumors that cannot be removed by surgery or have spread. The goal is to see if the combination is safe and works better than Enlonstobart alone. About 264 adults will tak…

This Phase 3 trial tests whether adding an experimental drug called SYS6010 to the standard treatment osimertinib can help people with a specific type of advanced lung cancer (EGFR-mutant NSCLC) live longer without their cancer getting worse. About 680 participants will be random…

This early-phase trial tests a new drug called SYS6051 in 114 adults with advanced solid tumors that have not responded to standard treatments. The study aims to find a safe dose and check for early signs of tumor shrinkage. Participants receive the drug by IV every three weeks.

This phase 3 study tests a new drug called SYS6002 against standard chemotherapy in 406 people with advanced bladder cancer (urothelial carcinoma) that has worsened after platinum chemo and immunotherapy. The main goal is to see if SYS6002 helps people live longer. The study is n…

This Phase 3 trial compares an experimental drug called SYS6010 with the standard chemotherapy docetaxel in about 506 people with advanced non-squamous non-small cell lung cancer that has not responded to prior treatments. The study aims to see if SYS6010 can slow cancer growth o…

This phase 3 study tests a new drug called SYS6010 against standard chemotherapy in people with advanced esophageal cancer that has worsened after at least one prior treatment. About 436 participants will be randomly assigned to receive either SYS6010 or a standard chemo drug. Th…

This study tests a new drug called SYS6010 against standard chemotherapy in people with a specific type of advanced breast cancer (HER2-negative, EGFR-positive) that has come back or spread. About 400 adults who have already tried 1-2 chemotherapy treatments will be randomly assi…

This Phase 2 trial compares a new drug called SYS6002 to the current standard treatment PADCEV in 100 people with advanced bladder cancer that has worsened after chemotherapy and immunotherapy. The study is not yet recruiting and will check for side effects and how well the drugs…

This Phase 2 trial tests whether adding SYS6010 to the standard drug osimertinib before surgery can improve outcomes for people with a specific type of lung cancer (EGFR-mutant non-squamous non-small cell lung cancer). About 120 participants with stage II-IIIB disease will receiv…

This study tests a new combination of drugs for people with advanced or metastatic esophageal squamous cell carcinoma who have not had prior treatment. The experimental therapy includes SYS6010 (a targeted antibody-drug conjugate) plus SG001 (an immunotherapy), with or without st…

This phase 3 trial tests whether the experimental drug SYS6002 works better than standard chemotherapy for people with recurrent or metastatic cervical cancer that has not responded to platinum chemo and immunotherapy. About 412 adults aged 18-75 will be randomly assigned to rece…